Skip to main content

Impact of the updated SOFA-2 score on organ dysfunction assessment and trial outcomes in Sepsis: A reanalysis of two randomized trials

Journal
Journal of critical care (Q1)
Published
4 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Shannon Leland, Hannah Bank, Tatyana Shvilkina, John H Lee, Noa Berlin, Cassandra Peitzman, et al.
PMID
42981694
DOI
10.1016/j.jcrc.2026.155809

Why clinicians should know about it

Abstract

BACKGROUND: The Sequential Organ Failure Assessment (SOFA) score is the standard tool for quantifying organ dysfunction in sepsis. The updated SOFA-2 score may alter interpretation of prior trials. We reanalyzed two adult sepsis randomized trials, Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) and Thiamine for Renal Protection in Septic Shock (TRPSS), to evaluate the impact of SOFA-2 on organ-specific scoring and trial interpretation. METHODS: Patient data were rescored using a best available SOFA-2 reconstruction. Subscores were compared between SOFA-1 and SOFA-2 at baseline, 24, 48, and 72 h using Wilcoxon signed-rank tests and Gwet's AC2. Trial outcomes were reanalyzed using linear mixed-effects models with SOFA-2. A post hoc, exploratory sensitivity analysis incorporated approximated urine output into the renal subscore. RESULTS: SOFA-2 produced lower total scores than SOFA-1 in both cohorts (ACTS 9 vs. 7; TRPSS 11 vs. 10; both p < 0.001), with lower respiratory and cardiovascular and higher coagulation subscores. For the ACTS primary outcome, SOFA-2 (mean difference [MD] -0.8, 95% CI -1.6 to 0.0, p = 0.06) was similar to SOFA-1 (MD -0.8, 95% CI -1.7 to 0.2, p = 0.12) but became significant in the post hoc, exploratory urine-output analysis (MD -0.84, 95% CI -1.64 to -0.05, p = 0.04). In TRPSS, SOFA-2 did not change overall interpretation but attenuated the treatment effect at all timepoints. CONCLUSIONS: SOFA-2 changes how organ dysfunction is defined and may influence interpretation of prior trials, particularly when urine output is included. These findings support SOFA-version transparency and prospective SOFA-2 validation. TRIAL REGISTRATION: ACTS: ClinicalTrials.gov (NCT03389555), registered December 28, 2017; TRPSS: ClinicalTrials.gov (NCT03550794), registered May 25, 2018.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.